TF and hemophilia: The in vivo efficacy study was also performed for oral administration and found out that oral rFIX-Tf/G2 elicited a significant effect on reducing blood loss in mutant hemophilia B mice, whereas oral rFIX-Tf/SVSQ was ineffective.